Generic placeholder image

Current Medicinal Chemistry

Author(s): Lijun Wang, Hailin Wang, Yiyang Luo, Wei Wu, Yibei Gui, Jiale Zhao, Ruisi Xiong, Xueqin Li, Ding Yuan* and Chengfu Yuan*

DOI: 10.2174/0929867331666230914091944

DownloadDownload PDF Flyer Cite As
Role of LncRNA MIAT in Diabetic Complications

Page: [1716 - 1725] Pages: 10

  • * (Excluding Mailing and Handling)

Abstract

Long non-coding RNA (LncRNA) refers to a large class of RNAs with over 200 nucleotides that do not have the function of encoding proteins. In recent years, more and more literature has revealed that lncRNA is involved in manipulating genes related to human health and disease, playing outstanding biological functions, which has attracted widespread attention from researchers. The newly discovered long-stranded non-coding RNA myocardial infarction-related transcript (LncRNA MIAT) is abnormally expressed in a variety of diseases, especially in diabetic complications, and has been proven to have a wide range of effects. This review article aimed to summarize the importance of LncRNA MIAT in diabetic complications, such as diabetic cardiomyopathy, diabetic nephropathy, and diabetic retinopathy, and highlight the latest findings on the pathway and mechanism of its participation in regulating diabetic complications, which may aid in finding new intervention targets for the treatment of diabetic complications. LncRNA MIAT competitively binds microRNAs to regulate gene expression as competitive endogenous RNAs. Thus, this review article has reviewed the biological function and pathogenesis of LncRNA MIAT in diabetic complications and described its role in diabetic complications. This paper will help in finding new therapeutic targets and intervention strategies for diabetes complications.

[1]
Kallapur, A.; Sallam, T. Endothelial cells LEENE on noncoding RNAs in diabetic vasculopathy. J. Clin. Invest., 2023, 133(3), e167047.
[http://dx.doi.org/10.1172/JCI167047] [PMID: 36719373]
[2]
Da, C.; Gong, C.Y.; Nan, W.; Zhou, K.S.; Wu, Z.L.; Zhang, H.H. The role of long non-coding RNA MIAT in cancers. Biomed. Pharmacother., 2020, 129, 110359.
[http://dx.doi.org/10.1016/j.biopha.2020.110359] [PMID: 32535389]
[3]
Ishii, N.; Ozaki, K.; Sato, H.; Mizuno, H.; Susumu Saito; Takahashi, A.; Miyamoto, Y.; Ikegawa, S.; Kamatani, N.; Hori, M.; Satoshi, S.; Nakamura, Y.; Tanaka, T. Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction. J. Hum. Genet., 2006, 51(12), 1087-1099.
[http://dx.doi.org/10.1007/s10038-006-0070-9] [PMID: 17066261]
[4]
Liao, J.; He, Q.; Li, M.; Chen, Y.; Liu, Y.; Wang, J. LncRNA MIAT: Myocardial infarction associated and more. Gene, 2016, 578(2), 158-161.
[http://dx.doi.org/10.1016/j.gene.2015.12.032] [PMID: 26707210]
[5]
Galaviz, K.I.; Weber, M.B.; Straus, A.; Haw, J.S.; Narayan, K.M.V.; Ali, M.K. Global diabetes prevention interventions: A systematic review and network meta-analysis of the real-world impact on incidence, weight, and glucose. Diabetes Care, 2018, 41(7), 1526-1534.
[http://dx.doi.org/10.2337/dc17-2222] [PMID: 29934481]
[6]
Alfaifi, M.; Ali Beg, M.M.; Alshahrani, M.Y.; Ahmad, I.; Alkhathami, A.G.; Joshi, P.C.; Alshehri, O.M.; Alamri, A.M.; Verma, A.K. Circulating long non-coding RNAs NKILA, NEAT1, MALAT1, and MIAT expression and their association in type 2 diabetes mellitus. BMJ Open Diabetes Res. Care, 2021, 9(1), e001821.
[http://dx.doi.org/10.1136/bmjdrc-2020-001821] [PMID: 33436407]
[7]
Boon, R.A.; Jaé, N.; Holdt, L.; Dimmeler, S. Long noncoding RNAs. J. Am. Coll. Cardiol., 2016, 67(10), 1214-1226.
[http://dx.doi.org/10.1016/j.jacc.2015.12.051] [PMID: 26965544]
[8]
Li, Y.; Li, J.; Chen, L.; Xu, L. The roles of long non-coding RNA in osteoporosis. Curr. Stem Cell Res. Ther., 2020, 15(7), 639-645.
[http://dx.doi.org/10.2174/1574888X15666200501235735] [PMID: 32357819]
[9]
Mattick, J.S.; Amaral, P.P.; Carninci, P.; Carpenter, S.; Chang, H.Y.; Chen, L.L.; Chen, R.; Dean, C.; Dinger, M.E.; Fitzgerald, K.A.; Gingeras, T.R.; Guttman, M.; Hirose, T.; Huarte, M.; Johnson, R.; Kanduri, C.; Kapranov, P.; Lawrence, J.B.; Lee, J.T.; Mendell, J.T.; Mercer, T.R.; Moore, K.J.; Nakagawa, S.; Rinn, J.L.; Spector, D.L.; Ulitsky, I.; Wan, Y.; Wilusz, J.E.; Wu, M. Long non-coding RNAs: Definitions, functions, challenges and recommendations. Nat. Rev. Mol. Cell Biol., 2023, 24(6), 430-447.
[http://dx.doi.org/10.1038/s41580-022-00566-8] [PMID: 36596869]
[10]
Ghafouri-Fard, S.; Khoshbakht, T.; Hussen, B.M.; Taheri, M.; Arefian, N. Regulatory role of non-coding RNAs on immune responses during sepsis. Front. Immunol., 2021, 12, 798713.
[http://dx.doi.org/10.3389/fimmu.2021.798713] [PMID: 34956235]
[11]
Tofigh, R.; Hosseinpourfeizi, M.; Baradaran, B.; Teimourian, S.; Safaralizadeh, R. Rheumatoid arthritis and non-coding RNAs; how to trigger inflammation. Life Sci., 2023, 315, 121367.
[http://dx.doi.org/10.1016/j.lfs.2023.121367] [PMID: 36639050]
[12]
Kretz, M.; Siprashvili, Z.; Chu, C.; Webster, D.E.; Zehnder, A.; Qu, K.; Lee, C.S.; Flockhart, R.J.; Groff, A.F.; Chow, J.; Johnston, D.; Kim, G.E.; Spitale, R.C.; Flynn, R.A.; Zheng, G.X.Y.; Aiyer, S.; Raj, A.; Rinn, J.L.; Chang, H.Y.; Khavari, P.A. Control of somatic tissue differentiation by the long non-coding RNA TINCR. Nature., 2013, 493(7431), 231-235.
[http://dx.doi.org/10.1038/nature11661] [PMID: 23201690]
[13]
Vance, K.W.; Ponting, C.P. Transcriptional regulatory functions of nuclear long noncoding RNAs. Trends Genet., 2014, 30(8), 348-355.
[http://dx.doi.org/10.1016/j.tig.2014.06.001] [PMID: 24974018]
[14]
Yu, B.; Wang, S. Angio-LncRs: LncRNAs that regulate angiogenesis and vascular disease. Theranostics, 2018, 8(13), 3654-3675.
[http://dx.doi.org/10.7150/thno.26024] [PMID: 30026873]
[15]
Ballantyne, M.D.; McDonald, R.A.; Baker, A.H. lncRNA/MicroRNA interactions in the vasculature. Clin. Pharmacol. Ther., 2016, 99(5), 494-501.
[http://dx.doi.org/10.1002/cpt.355] [PMID: 26910520]
[16]
Cech, T.R.; Steitz, J.A. The noncoding RNA revolution- trashing old rules to forge new ones. Cell, 2014, 157(1), 77-94.
[http://dx.doi.org/10.1016/j.cell.2014.03.008] [PMID: 24679528]
[17]
Ahn, Y.H.; Kim, J.S. Long non-coding RNAs as regulators of interactions between cancer-associated fibroblasts and cancer cells in the tumor microenvironment. Int. J. Mol. Sci., 2020, 21(20), 7484.
[http://dx.doi.org/10.3390/ijms21207484] [PMID: 33050576]
[18]
Paldino, G.; Fierabracci, A. Shedding new light on the role of ERAP1 in Type 1 diabetes: A perspective on disease management. Autoimmun. Rev., 2023, 22(4), 103291.
[http://dx.doi.org/10.1016/j.autrev.2023.103291] [PMID: 36740089]
[19]
Kim, D.H.; Park, J.S.; Choi, H.I.; Kim, C.S.; Bae, E.H.; Ma, S.K.; Kim, S.W. The role of the farnesoid X receptor in kidney health and disease: A potential therapeutic target in kidney diseases. Exp. Mol. Med., 2023, 55(2), 304-312.
[http://dx.doi.org/10.1038/s12276-023-00932-2] [PMID: 36737665]
[20]
Jiang, S.; Fang, J.; Li, W. Protein restriction for diabetic kidney disease. Cochrane Libr., 2023, 2023(1), CD014906.
[http://dx.doi.org/10.1002/14651858.CD014906.pub2] [PMID: 36594428]
[21]
Lim, L.L.; Chow, E.; Chan, J.C.N. Cardiorenal diseases in type 2 diabetes mellitus: Clinical trials and real-world practice. Nat. Rev. Endocrinol., 2023, 19(3), 151-163.
[http://dx.doi.org/10.1038/s41574-022-00776-2] [PMID: 36446898]
[22]
Zheng, Y.; Ley, S.H.; Hu, F.B. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat. Rev. Endocrinol., 2018, 14(2), 88-98.
[http://dx.doi.org/10.1038/nrendo.2017.151] [PMID: 29219149]
[23]
Zhao, X.; Ling, F.; Zhang, G.; Yu, N.; Yang, J.; Xin, X. The correlation between MicroRNAs and diabetic retinopathy. Front. Immunol., 2022, 13, 941982.
[http://dx.doi.org/10.3389/fimmu.2022.941982] [PMID: 35958584]
[24]
Zhu, J.; Han, J.; Liu, L.; Liu, Y.; Xu, W.; Li, X.; Yang, L.; Gu, Y.; Tang, W.; Shi, Y.; Ye, S.; Hua, F.; Xiang, G.; Liu, M.; Sun, Z.; Su, Q.; Li, X.; Li, Y.; Li, Y.; Li, H.; Li, Y.; Yang, T.; Yang, J.; Shi, L.; Yu, X.; Chen, L.; Shao, J.; Liang, J.; Han, X.; Xue, Y.; Ma, J.; Zhu, D.; Mu, Y. Clinical expert consensus on the assessment and protection of pancreatic islet β-cell function in type 2 diabetes mellitus. Diabetes Res. Clin. Pract., 2023, 197, 110568.
[http://dx.doi.org/10.1016/j.diabres.2023.110568] [PMID: 36738836]
[25]
Dwivedi, K.K.; Lakhani, P.; Sihota, P.; Tikoo, K.; Kumar, S.; Kumar, N. The multiscale characterization and constitutive modeling of healthy and type 2 diabetes mellitus Sprague Dawley rat skin. Acta Biomater., 2022, 158, 324-346.
[http://dx.doi.org/10.1016/j.actbio.2022.12.037] [PMID: 36565785]
[26]
Liu, M.; Peng, T.; Hu, L.; Wang, M.; Guo, D.; Qi, B.; Ren, G.; Wang, D.; Li, Y.; Song, L.; Hu, J.; Li, Y. N-glycosylation-mediated CD147 accumulation induces cardiac fibrosis in the diabetic heart through ALK5 activation. Int. J. Biol. Sci., 2023, 19(1), 137-155.
[http://dx.doi.org/10.7150/ijbs.77469] [PMID: 36594096]
[27]
Zhou, X.; Zhang, W.; Jin, M.; Chen, J.; Xu, W.; Kong, X. lncRNA MIAT functions as a competing endogenous RNA to upregulate DAPK2 by sponging miR-22-3p in diabetic cardiomyopathy. Cell Death Dis., 2017, 8(7), e2929.
[http://dx.doi.org/10.1038/cddis.2017.321] [PMID: 28703801]
[28]
Pant, T.; Dhanasekaran, A.; Fang, J.; Bai, X.; Bosnjak, Z.J.; Liang, M.; Ge, Z.D. Current status and strategies of long noncoding RNA research for diabetic cardiomyopathy. BMC Cardiovasc. Disord., 2018, 18(1), 197.
[http://dx.doi.org/10.1186/s12872-018-0939-5] [PMID: 30342478]
[29]
Sohrabifar, N.; Ghaderian, S.M.H.; Alipour Parsa, S.; Ghaedi, H.; Jafari, H. Variation in the expression level of MALAT1, MIAT and XIST lncRNAs in coronary artery disease patients with and without type 2 diabetes mellitus. Arch. Physiol. Biochem., 2022, 128(5), 1308-1315.
[http://dx.doi.org/10.1080/13813455.2020.1768410] [PMID: 32447981]
[30]
Yu, Y.; Dong, Y.; Deng, B.; Yang, T. IncRNA MIAT accelerates keloid formation by miR-411-5p/JAG1 axis. Crit. Rev. Eukaryot. Gene Expr., 2023, 33(2), 81-92.
[http://dx.doi.org/10.1615/CritRevEukaryotGeneExpr.2022044734] [PMID: 36734859]
[31]
Qu, X.; Du, Y.; Shu, Y.; Gao, M.; Sun, F.; Luo, S.; Yang, T.; Zhan, L.; Yuan, Y.; Chu, W.; Pan, Z.; Wang, Z.; Yang, B.; Lu, Y. MIAT is a pro-fibrotic long non-coding RNA governing cardiac fibrosis in post-infarct myocardium. Sci. Rep., 2017, 7(1), 42657.
[http://dx.doi.org/10.1038/srep42657] [PMID: 28198439]
[32]
Yao, L.; Zhou, B.; You, L.; Hu, H.; Xie, R. LncRNA MIAT/miR-133a-3p axis regulates atrial fibrillation and atrial fibrillation-induced myocardial fibrosis. Mol. Biol. Rep., 2020, 47(4), 2605-2617.
[http://dx.doi.org/10.1007/s11033-020-05347-0] [PMID: 32130618]
[33]
García-Padilla, C.; Domínguez, J.N.; Aránega, A.E.; Franco, D. Differential chamber-specific expression and regulation of long non-coding RNAs during cardiac development. Biochim. Biophys. Acta. Gene Regul. Mech., 2019, 1862(10), 194435.
[http://dx.doi.org/10.1016/j.bbagrm.2019.194435] [PMID: 31678627]
[34]
Xiao, W.; Zheng, D.; Chen, X.; Yu, B.; Deng, K.; Ma, J.; Wen, X.; Hu, Y.; Hou, J. Long non-coding RNA MIAT is involved in the regulation of pyroptosis in diabetic cardiomyopathy via targeting miR-214-3p. iScience, 2021, 24(12), 103518.
[http://dx.doi.org/10.1016/j.isci.2021.103518] [PMID: 34950859]
[35]
Tao, P.; Ji, J.; Wang, Q.; Cui, M.; Cao, M.; Xu, Y. The role and mechanism of gut microbiota-derived short-chain fatty in the prevention and treatment of diabetic kidney disease. Front. Immunol., 2022, 13, 1080456.
[http://dx.doi.org/10.3389/fimmu.2022.1080456] [PMID: 36601125]
[36]
Wang, X.; Zhao, J.; Li, Y.; Rao, J.; Xu, G. Epigenetics and endoplasmic reticulum in podocytopathy during diabetic nephropathy progression. Front. Immunol., 2022, 13, 1090989.
[http://dx.doi.org/10.3389/fimmu.2022.1090989] [PMID: 36618403]
[37]
Rayego-Mateos, S.; Rodrigues-Diez, R.R.; Fernandez-Fernandez, B.; Mora-Fernández, C.; Marchant, V.; Donate- Correa, J.; Navarro-González, J.F.; Ortiz, A.; Ruiz-Ortega, M. Targeting inflammation to treat diabetic kidney disease: The road to 2030. Kidney Int., 2023, 103(2), 282-296.
[http://dx.doi.org/10.1016/j.kint.2022.10.030] [PMID: 36470394]
[38]
Forst, T.; Mathieu, C.; Giorgino, F.; Wheeler, D.C.; Papanas, N.; Schmieder, R.E.; Halabi, A.; Schnell, O.; Streckbein, M.; Tuttle, K.R. New strategies to improve clinical outcomes for diabetic kidney disease. BMC Med., 2022, 20(1), 337.
[http://dx.doi.org/10.1186/s12916-022-02539-2] [PMID: 36210442]
[39]
Akhtar, M.; Taha, N.M.; Nauman, A.; Mujeeb, I.B.; Al-Nabet, A.D.M.H. Diabetic kidney disease: Past and present. Adv. Anat. Pathol., 2020, 27(2), 87-97.
[http://dx.doi.org/10.1097/PAP.0000000000000257] [PMID: 31876542]
[40]
Zhao, Y.; Yan, G.; Mi, J.; Wang, G.; Yu, M.; Jin, D.; Tong, X.; Wang, X. The impact of lncRNA on diabetic kidney disease: Systematic review and in silico analyses. Comput. Intell. Neurosci., 2022, 2022, 1-17.
[http://dx.doi.org/10.1155/2022/8400106] [PMID: 35528328]
[41]
Ghafouri-Fard, S.; Abak, A.; Talebi, S.F.; Shoorei, H.; Branicki, W.; Taheri, M.; Akbari Dilmaghani, N. Role of miRNA and lncRNAs in organ fibrosis and aging. Biomed. Pharmacother., 2021, 143, 112132.
[http://dx.doi.org/10.1016/j.biopha.2021.112132] [PMID: 34481379]
[42]
Wang, Z.; Zhang, B.; Chen, Z.; He, Y.; Ru, F.; Liu, P.; Chen, X. The long noncoding RNA myocardial infarction-associated transcript modulates the epithelial-mesenchymal transition in renal interstitial fibrosis. Life Sci., 2020, 241, 117187.
[http://dx.doi.org/10.1016/j.lfs.2019.117187] [PMID: 31863776]
[43]
Liu, Y.; Xu, Z.; Ma, F.; Jia, Y.; Wang, G. Knockdown of TLR4 attenuates high glucose-induced podocyte injury via the NALP3/ASC/Caspase-1 signaling pathway. Biomed. Pharmacother., 2018, 107, 1393-1401.
[http://dx.doi.org/10.1016/j.biopha.2018.08.134] [PMID: 30257355]
[44]
Zhang, M.; Zhao, S.; Xu, C.; Shen, Y.; Huang, J.; Shen, S.; Li, Y.; Chen, X. Ablation of lncRNA MIAT mitigates high glucose-stimulated inflammation and apoptosis of podocyte via miR-130a-3p/TLR4 signaling axis. Biochem. Biophys. Res. Commun., 2020, 533(3), 429-436.
[http://dx.doi.org/10.1016/j.bbrc.2020.09.034] [PMID: 32972755]
[45]
Tan, T.E.; Wong, T.Y. Diabetic retinopathy: Looking forward to 2030. Front. Endocrinol., 2023, 13, 1077669.
[http://dx.doi.org/10.3389/fendo.2022.1077669] [PMID: 36699020]
[46]
Teo, Z.L.; Tham, Y.C.; Yu, M.; Chee, M.L.; Rim, T.H.; Cheung, N.; Bikbov, M.M.; Wang, Y.X.; Tang, Y.; Lu, Y.; Wong, I.Y.; Ting, D.S.W.; Tan, G.S.W.; Jonas, J.B.; Sabanayagam, C.; Wong, T.Y.; Cheng, C.Y. Global prevalence of diabetic retinopathy and projection of burden through 2045. Ophthalmology., 2021, 128(11), 1580-1591.
[http://dx.doi.org/10.1016/j.ophtha.2021.04.027] [PMID: 33940045]
[47]
Cai, C.; Meng, C.; He, S.; Gu, C.; Lhamo, T.; Draga, D.; Luo, D.; Qiu, Q. DNA methylation in diabetic retinopathy: Pathogenetic role and potential therapeutic targets. Cell Biosci., 2022, 12(1), 186.
[http://dx.doi.org/10.1186/s13578-022-00927-y] [PMID: 36397159]
[48]
Elafros, M.A.; Callaghan, B.C.; Skolarus, L.E.; Vileikyte, L.; Lawrenson, J.G.; Feldman, E.L. Patient and health care provider knowledge of diabetes and diabetic microvascular complications: A comprehensive literature review. Rev. Endocr. Metab. Disord., 2022, 24(2), 221-239.
[http://dx.doi.org/10.1007/s11154-022-09754-5] [PMID: 36322296]
[49]
Yue, T.; Shi, Y.; Luo, S.; Weng, J.; Wu, Y.; Zheng, X. The role of inflammation in immune system of diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Front. Immunol., 2022, 13, 1055087.
[http://dx.doi.org/10.3389/fimmu.2022.1055087] [PMID: 36582230]
[50]
Kaur, P.; Kotru, S.; Singh, S.; Munshi, A. Role of miRNAs in diabetic neuropathy: Mechanisms and possible interventions. Mol. Neurobiol., 2022, 59(3), 1836-1849.
[http://dx.doi.org/10.1007/s12035-021-02662-w] [PMID: 35023058]
[51]
Alves, C.H.; Fernandes, R.; Santiago, A.R.; Ambrósio, A.F. Microglia contribution to the regulation of the retinal and choroidal vasculature in age-related macular degeneration. Cells., 2020, 9(5), 1217.
[http://dx.doi.org/10.3390/cells9051217] [PMID: 32423062]
[52]
Zhang, J.; Chen, M.; Chen, J.; Lin, S.; Cai, D.; Chen, C.; Chen, Z. Long non-coding RNA MIAT acts as a biomarker in diabetic retinopathy by absorbing miR-29b and regulating cell apoptosis. Biosci. Rep., 2017, 37(2), BSR20170036.
[http://dx.doi.org/10.1042/BSR20170036] [PMID: 28246353]
[53]
Yan, B.; Yao, J.; Liu, J.Y.; Li, X.M.; Wang, X.Q.; Li, Y.J.; Tao, Z.F.; Song, Y.C.; Chen, Q.; Jiang, Q. lncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA. Circ. Res., 2015, 116(7), 1143-1156.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.305510] [PMID: 25587098]
[54]
Yu, X.; Ma, X.; Lin, W.; Xu, Q.; Zhou, H.; Kuang, H. Long noncoding RNA MIAT regulates primary human retinal pericyte pyroptosis by modulating miR-342–3p targeting of CASP1 in diabetic retinopathy. Exp. Eye Res., 2021, 202, 108300.
[http://dx.doi.org/10.1016/j.exer.2020.108300] [PMID: 33065089]
[55]
Biswas, S.; Coyle, A.; Chen, S.; Gostimir, M.; Gonder, J.; Chakrabarti, S. Expressions of serum lncRNAs in diabetic retinopathy – a potential diagnostic tool. Front. Endocrinol., 2022, 13, 851967.
[http://dx.doi.org/10.3389/fendo.2022.851967] [PMID: 35464068]
[56]
Cao, W.; Zhang, N.; He, X.; Xing, Y.; Yang, N. Long non- coding RNAs in retinal neovascularization: current research and future directions. Graefes Arch. Clin. Exp. Ophthalmol., 2022.
[http://dx.doi.org/10.1007/s00417-022-05843-y] [PMID: 36171459]
[57]
Zhu, X.; Li, Q.; George, V.; Spanoudis, C.; Gilkes, C.; Shrestha, N.; Liu, B.; Kong, L.; You, L.; Echeverri, C.; Li, L.; Wang, Z.; Chaturvedi, P.; Muniz, G.J.; Egan, J.O.; Rhode, P.R.; Wong, H.C. A novel interleukin-2-based fusion molecule, HCW9302, differentially promotes regulatory T cell expansion to treat atherosclerosis in mice. Front. Immunol., 2023, 14, 1114802.
[http://dx.doi.org/10.3389/fimmu.2023.1114802] [PMID: 36761778]
[58]
Xu, S.; Pelisek, J.; Jin, Z.G. Atherosclerosis is an epigenetic disease. Trends Endocrinol. Metab., 2018, 29(11), 739-742.
[http://dx.doi.org/10.1016/j.tem.2018.04.007] [PMID: 29753613]
[59]
Fasolo, F.; Jin, H.; Winski, G.; Chernogubova, E.; Pauli, J.; Winter, H.; Li, D.Y.; Glukha, N.; Bauer, S.; Metschl, S.; Wu, Z.; Koschinsky, M.L.; Reilly, M.; Pelisek, J.; Kempf, W.; Eckstein, H.H.; Soehnlein, O.; Matic, L.; Hedin, U.; Bäcklund, A.; Bergmark, C.; Paloschi, V.; Maegdefessel, L. Long noncoding RNA MIAT controls advanced atherosclerotic lesion formation and plaque destabilization. Circulation., 2021, 144(19), 1567-1583.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.120.052023] [PMID: 34647815]
[60]
Wu, L.; Pei, Y.; Zhu, Y.; Jiang, M.; Wang, C.; Cui, W.; Zhang, D. Association of N6-methyladenine DNA with plaque progression in atherosclerosis via myocardial infarction-associated transcripts. Cell Death Dis., 2019, 10(12), 909.
[http://dx.doi.org/10.1038/s41419-019-2152-6] [PMID: 31797919]
[61]
Sun, G.; Li, Y.; Ji, Z. Up-regulation of MIAT aggravates the atherosclerotic damage in atherosclerosis mice through the activation of PI3K/Akt signaling pathway. Drug Deliv., 2019, 26(1), 641-649.
[http://dx.doi.org/10.1080/10717544.2019.1628116] [PMID: 31237148]
[62]
Zhou, Y.; Ma, W.; Bian, H.; Chen, Y.; Li, T.; Shang, D.; Sun, H. Long non-coding RNA MIAT/miR-148b/PAPPA axis modifies cell proliferation and migration in ox-LDL-induced human aorta vascular smooth muscle cells. Life Sci., 2020, 256, 117852.
[http://dx.doi.org/10.1016/j.lfs.2020.117852] [PMID: 32470448]
[63]
Han, X.; Cai, L.; Shi, Y.; Hua, Z.; Lu, Y.; Li, D.; Yang, J. Integrated analysis of long non-coding RNA-mRNA profile and validation in diabetic cataract. Curr. Eye Res., 2022, 47(3), 382-390.
[http://dx.doi.org/10.1080/02713683.2021.1984536] [PMID: 35068271]
[64]
Meydan, C.; Üçeyler, N.; Soreq, H. Non-coding RNA regulators of diabetic polyneuropathy. Neurosci. Lett., 2020, 731, 135058.
[http://dx.doi.org/10.1016/j.neulet.2020.135058] [PMID: 32454150]
[65]
Meydan, C.; Bekenstein, U.; Soreq, H. Molecular regulatory pathways link sepsis with metabolic syndrome: Non- coding RNA elements underlying the sepsis/metabolic cross-talk. Front. Mol. Neurosci., 2018, 11, 189.
[http://dx.doi.org/10.3389/fnmol.2018.00189] [PMID: 29922126]
[66]
Huo, W.; Hou, Y.; Li, Y.; Li, H. Downregulated lncRNA-MIAT confers protection against erectile dysfunction by downregulating lipoprotein lipase via activation of miR-328a-5p in diabetic rats. Biochim. Biophys. Acta Mol. Basis Dis., 2019, 1865(6), 1226-1240.
[http://dx.doi.org/10.1016/j.bbadis.2019.01.018] [PMID: 30660685]